These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 28359194)

  • 1. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data Monitoring Committees: Current issues.
    Fleming TR; Ellenberg SS; DeMets DL
    Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
    Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
    J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A third trial oversight committee: Functions, benefits and issues.
    Lane JA; Gamble C; Cragg WJ; Tembo D; Sydes MR
    Clin Trials; 2020 Feb; 17(1):106-112. PubMed ID: 31665920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liability issues for data monitoring committee members.
    DeMets DL; Fleming TR; Rockhold F; Massie B; Merchant T; Meisel A; Mishkin B; Wittes J; Stump D; Califf R
    Clin Trials; 2004; 1(6):525-31. PubMed ID: 16279293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A joint industry-sponsored data monitoring committee model for observational, retrospective drug safety studies in the real-world setting.
    Major-Pedersen A; McCullen MK; Sabol ME; Adetunji O; Massaro J; Neugut AI; Sosa JA; Hollenberg AN
    Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):9-16. PubMed ID: 33179845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bringing data monitoring committee charters into the sunlight.
    DeMets DL; Zarin DA; Rockhold F; Ellenberg SS; Fleming T; Wittes J
    Clin Trials; 2023 Aug; 20(4):447-451. PubMed ID: 37231737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protecting the confidentiality of interim data: addressing current challenges.
    Fleming TR
    Clin Trials; 2015 Feb; 12(1):5-11. PubMed ID: 25475877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsors.
    Bhattacharyya A; Gallo P; Crisp A; LaVange L; Molenberghs G; Pétavy F; Seltzer J
    Biom J; 2019 Sep; 61(5):1232-1241. PubMed ID: 30589102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responsibilities of Data Monitoring Committees: Consensus Recommendations.
    Bierer BE; Li R; Seltzer J; Sleeper LA; Frank E; Knirsch C; Aldinger CE; Levine RJ; Massaro J; Shah A; Barnes M; Snapinn S; Wittes J
    Ther Innov Regul Sci; 2016 Sep; 50(5):648-659. PubMed ID: 30231760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the role and function of trial steering committees: results of an expert panel meeting.
    Harman NL; Conroy EJ; Lewis SC; Murray G; Norrie J; Sydes MR; Lane JA; Altman DG; Baigent C; Bliss JM; Campbell MK; Elbourne D; Evans S; Sandercock P; Gamble C
    Trials; 2015 Dec; 16():597. PubMed ID: 26715378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent data monitoring committees: preparing a path for the future.
    Hess CN; Roe MT; Gibson CM; Temple RJ; Pencina MJ; Zarin DA; Anstrom KJ; Alexander JH; Sherman RE; Fiedorek FT; Mahaffey KW; Lee KL; Chow SC; Armstrong PW; Califf RM
    Am Heart J; 2014 Aug; 168(2):135-41.e1. PubMed ID: 25066551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.